IRBM is a leading contract research organization (CRO) specializing in drug discovery and development. They offer a wide range of services to the biopharmaceutical industry, including target validation, hit identification, lead optimization, and preclinical development.
Established in 1992 as a research spin-off of the Merck Sharp & Dohme (MSD) pharmaceutical group.
Originally focused on infectious and respiratory diseases research.
Expanded its capabilities to cover multiple therapeutic areas, including oncology, neuroscience, and metabolic diseases.
Partnered with various pharmaceutical and biotech companies to support their drug discovery and development programs.
Became a key player in drug development in Italy and internationally.
A global CRO providing a range of services, including drug discovery, safety assessment, and clinical support.
A global CRO offering services for drug development, from early discovery to post-marketing support.
A leading provider of integrated information and technology-enabled healthcare services.
Offering target identification, hit exploration, lead optimization, and preclinical development services.
Providing process development and manufacturing of biological products, including viral vectors and recombinant proteins.
Expertise in vaccine research and development, from early-stage discovery to clinical testing.
IRBM offers a range of services including drug discovery, preclinical development, biomanufacturing, and vaccine R&D.
IRBM competes with companies like Charles River Laboratories, Covance, and QuintilesIMS in the contract research organization (CRO) space.
IRBM was founded in 1992 as a research spin-off of the Merck Sharp & Dohme (MSD) pharmaceutical group.
IRBM covers multiple therapeutic areas, including infectious diseases, respiratory diseases, oncology, neuroscience, and metabolic diseases.
Yes, IRBM partners with various pharmaceutical and biotech companies to support their drug discovery and development programs.